Received Feb 12, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | K2BB7 | — |
mild HSV reactivation in V1 Dermatome, L side forehead; This non-serious case was reported by a nurse via sales rep and described the occurrence of herpes simplex in a 53-year-old female patient who received Herpes zoster (Shingrix) (batch number K2BB7) for prophylaxis. On 25-FEB-2025, the patient received the 1st dose of Shingrix. On an unknown date, 5 days after receiving Shingrix, the patient experienced herpes simplex (Verbatim: mild HSV reactivation in V1 Dermatome, L side forehead). The outcome of the herpes simplex was resolved. It was unknown if the reporter considered the herpes simplex to be related to Shingrix. It was unknown if the company considered the herpes simplex to be related to Shingrix. Linked case(s) involving the same patient: US2026AMR003065 Additional Information: GSK Receipt Date: 09-JAN-2026 Post Shingrix vaccination patient experienced mild herpes simplex virus reactivation in V1 dermatome, left side forehead and 1 single pruritic vesicle approximately 5-10 days after vaccination. It was resolved without incident within 7 days, no need for any clinical intervention.; Sender's Comments: US-GSK-US2026AMR003065:Case ID for Second dose of Shingrix